What is the diagnosis and appropriate management for a patient whose hemoglobin electrophoresis shows approximately 80% hemoglobin S, 14% hemoglobin F, and 6% hemoglobin A2?

Diagnosis: Sickle Cell Anemia (HbSS) with Elevated Fetal Hemoglobin

This hemoglobin electrophoresis pattern (80% HbS, 14% HbF, 6% HbA2, 0% HbA) is diagnostic of homozygous sickle cell disease (HbSS), not sickle-beta thalassemia. The absence of HbA definitively rules out sickle-beta plus (β+) thalassemia, while the elevated HbA2 at 6% represents a common laboratory artifact when measuring samples containing HbS by HPLC methods 1.

Key Diagnostic Features

The electrophoresis pattern confirms:

• HbSS genotype: 80-95% HbS with 0% HbA is characteristic of homozygous sickle cell anemia 1
• Elevated HbF at 14%: This is significantly higher than the typical 5-15% range and indicates a milder phenotype with better prognosis 1
• Apparent HbA2 elevation: The 6% HbA2 is falsely elevated due to HPLC methodology artifact in HbS-containing samples 2, 3

Critical Pitfall: HbA2 Misinterpretation

Do not diagnose sickle-beta thalassemia based on elevated HbA2 alone. HPLC systems routinely produce falsely elevated HbA2 measurements (mean 3.90% ± 1.08% in HbSS samples vs. 2.57% ± 0.25% in normal individuals) when analyzing samples containing HbS 2. The HbA2 levels in HbS-containing samples partially overlap with beta-thalassemia carrier ranges (4-9%), leading to potential diagnostic confusion 2, 3.

Disease Severity Classification

This patient has severe sickle cell disease (HbSS) but with a favorable modifier 1:

• Expected baseline hemoglobin: 60-90 g/L (6-9 g/dL)
• Clinical severity: Typically severe with early onset painful crises
• Protective factor: HbF >8% (patient has 14%) reduces HbS polymerization and provides significant protection, resulting in milder phenotype with fewer symptoms 1

Management Approach

Immediate Actions

1. Refer to specialist hematology clinic for comprehensive multidisciplinary care - survival to 7th decade is expected with optimal management 1

2. Initiate hydroxycarbamide (hydroxyurea) therapy - this is now recommended as standard therapy for HbSS patients as it raises HbF levels further and reduces complications 1

3. Establish baseline laboratory values: Complete blood count, reticulocyte count, liver function tests, renal function

Ongoing Management Priorities

Prevention of acute complications:

• Vaso-occlusive painful crises
• Acute chest syndrome (life-threatening with new pulmonary infiltrate, respiratory symptoms, chest pain, hypoxemia) 4
• Stroke (requires urgent evaluation for any acute neurologic symptoms) 4
• Splenic sequestration (rapidly enlarging spleen with Hb drop >2 g/dL) 4
• Priapism (episodes >4 hours require emergency intervention) 5, 4, 5
• Infection (increased susceptibility requires vigilance) 1

Chronic disease management:

• Regular monitoring for end-organ damage (stroke, pulmonary hypertension, priapism, renal dysfunction)
• Vaccination schedule optimization
• Folic acid supplementation for chronic hemolysis
• Pain management protocols
• Transfusion support when indicated

Perioperative Considerations (If Surgery Required)

For low-to-moderate risk surgery 1, 6:

• Preoperative transfusion recommended if baseline Hb <90 g/L
• Target posttransfusion Hb: 90-110 g/L (never exceed 110 g/L to avoid hyperviscosity)
• Simple transfusion appropriate if Hb <90 g/L
• Exchange transfusion considered if Hb >90-100 g/L or for high-risk surgery

For high-risk surgery (neurosurgery, cardiac surgery) 1, 6:

• Exchange transfusion to reduce HbS% to <30%
• Target Hb 100-110 g/L
• Coordinate with hematology team minimum 72 hours before surgery

Blood product requirements 1:

• HbS-negative donor cells
• ABO, Rh, and Kell compatible
• Phenotype/genotype matched when possible
• Blood <10 days old for simple transfusion, <8 days for exchange

Genetic Counseling

Provide family counseling regarding inheritance pattern and screening recommendations for siblings and future offspring 7.